Epigenomics AG: Executive Board member Jens Ravens leaves the Company on
April 30, 2024

EQS-News: Epigenomics AG / Key word(s): Personnel
Epigenomics AG: Executive Board member Jens Ravens leaves the Company on
April 30, 2024

30.04.2024 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Epigenomics AG: Executive Board member Jens Ravens leaves the Company on
April 30, 2024

Berlin (Germany), April 30, 2024 - Jens Ravens, Executive Board member of
Epigenomics AG (Frankfurt General Standard: ECX, the "Company"), leaves the
Executive Board of the Company with effect as of April 30, 2024 due to the
successful transfer of nearly all assets of the Company to New Day
Diagnostics LLC.

Dr. Helge Lubenow, Chairwoman of the Supervisory Board of Epigenomics AG,
thanked Jens Ravens on behalf of the entire Supervisory Board: "Jens Ravens
accompanied the company during a very difficult phase and in particular made
significant contributions to secure the continued existence of Epigenomics
AG, both through the restructuring initiated since the beginning of 2023 and
through the sale of almost all of the company's assets to New Day
Diagnostics LLC. As proposed by the Executive and Supervisory Board, the
Extraordinary Shareholders' Meeting on September 11, 2023 approved the sale
of nearly all assets to NDD with an overwhelming majority. The Supervisory
Board considers the sale as the most promising way to create value for our
shareholders in the current situation. We deeply regret the departure of
Jens Ravens and wish him all the best for the future."

As of February 2022, Jens Ravens initially served as Chief Financial Officer
and was, since the departure of CEO Greg Hamilton on June 30, 2023 until
January 31, 2024, sole member of the Executive Board of Epigenomics AG.

As of May 1, 2024, Hansjörg Plaggemars will manage the company as sole
member of the Executive Board.

Contact:
Company
Epigenomics AG, Bertha-Benz-Strasse 5, 10557 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email:
contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: ir@epigenomics.com


Note on forward-looking statements

This publication expressly or implicitly contains forward-looking statements
concerning Epigenomics AG and its business. These statements involve certain
known and unknown risks, uncertainties and other factors that may cause
Epigenomics AG's actual results, financial condition and performance to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Epigenomics makes
this announcement as of the date of this release and does not intend to
update any forward-looking statements contained herein as a result of new
information or future events or otherwise.


---------------------------------------------------------------------------

30.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Epigenomics AG
                   Bertha-Benz-Straße 5
                   10557 Berlin
                   Germany
   Phone:          +49 30 24345-0
   Fax:            +49 30 24345-555
   E-mail:         ir@epigenomics.com
   Internet:       www.epigenomics.com
   ISIN:           DE000A37FT41
   WKN:            A37FT4
   Listed:         Regulated Market in Frankfurt (General Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1893193

End of News EQS News Service
---------------------------------------------------------------------------

1893193 30.04.2024 CET/CEST